Download

Download Full Text (3.5 MB)

Description

  • Whole breast irradiation (WBI) has been used in the treatment of breast cancer patients after partial mastectomy.
  • There has been increasing utilization of hypofractionated whole breast irradiation (HWBI), defined as a larger daily dose and fewer fractions compared to conventionally fractionated whole breast irradiation (CWBI). However, HWBI for patients with early-stage, biologically high-risk breast cancer remains relatively low.
  • We define biologically high-risk breast cancer as either triple negative (estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (Her-2) negative), Her-2 amplified, and/or patients with a high-risk multigene assay.
  • The 2018 ASTRO guidelines form the basis for treating breast cancer patients with HWBI. In regards to breast cancer receptor status, there is only a “moderate” quality of evidence leading to a conditional recommendation of HWBI for breast cancer patients with varying hormone receptor and Her-2 status.
  • The underrepresentation of patients with biologically high-risk breast cancer in prior studies comparing HWBI and CWBI also contributed to physician reluctance in offering HWBI to this patient population.
  • • The primary goal of this study is to compare the clinical outcomes of CWBI versus moderate HWBI in patients with early-stage, biologically high-risk breast cancer.

Publication Date

5-2024

Keywords

breast irradiation

Disciplines

Oncology | Radiology

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2024.

Clinical Outcomes of Hypofractionated Whole Breast Irradiation In Early Stage, Biologically High-Risk Breast Cancer

Share

COinS